- Peginterferon alfa-2a
Peginterferon alfa-2a Clinical data AHFS/Drugs.com MedlinePlus Pregnancy cat. ? Legal status ? Routes subcutaneous Identifiers CAS number ATC code L03
L03 (in combinations)
DrugBank UNII KEGG ChEMBL Chemical data Formula C860H1353N227O255S9 Mol. mass 19241 g/mol (unpegylated)
40000 g/mol (pegylated)
(what is this?)
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.
This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.
Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections. Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system.
Host genetic factors influencing treatment response
For genotype 1 hepatitis C treated with Pegylated interferon-alpha-2a or Pegylated interferon-alpha-2b (brand names Pegasys or PEG-Intron) combined with ribavirin, it has been shown genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature , showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Later report from Nature  demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.
- ^ Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401. doi:10.1038/nature08309. PMID 19684573.
- ^ Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature 461 (7265): 798–801. doi:10.1038/nature08463. PMID 19759533.
- Interferon and hepatitis c at pegasys.com
- PMPRB at pmprb-cepmb.gc.ca
- Chemical structure at hepalife.com
- MeSH Pegasys
Cell signaling: cytokines By familyCCLCXCLCX3CLXCLType I
subunit)IL6 like/gp130IL-12 family/IL12RB1OtherIL-10 familyIL-17 familyOther
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp) DNA virus antivirals (primarily J05, also S01AD and D06BB) Baltimore IDNA-synthesis
inhibitorTK activatedNot TK activatedOther
Hepatitis B (VII) Multiple/generalNucleic acid inhibitorsInterferon alfa-2b • Peginterferon alfa-2aMultiple/unknownErbB2/PI3K PathwayNOV-205§ • NOV-002† #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III RNA virus antivirals (primarily J05, also S01AD and D06BB) Hepatitis C Picornavirus Anti-influenza agents Multiple/generalInterferon alfa-2b • Peginterferon alfa-2aMultiple/unknown #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.